Guidelines for the diagnosis and management of migraine in clinical practice

CMAJ. Canadian Medical Association Journal

Volumn 156, Issue 9, 1997, Pages 1273-1287

  Pryse Phillips, William E M ^a,b,p   Dodick, David W ^c,d,p   Edmeads, John G ^e,p   Gawel, Marek J ^e,f,g,p   Nelson, Robert F ^h,i,p   Allan Purdy, R ^p   Robinson, Gordon ^l,m,p   Stirling, Denise ^n,p   Worthington, Irene ^o,p  

^a Health Sciences Centre St John's   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g Centenary Health Centre   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j DALHOUSIE UNIVERSITY   (Canada)

^k QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m VANCOUVER GENERAL HOSPITAL   (Canada)

ⁿ Oakville Trafalgar Memorial Hospital   (Canada)

^o UNIVERSITY OF TORONTO   (Canada)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTALBITAL; BUTORPHANOL; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CODEINE; DEXAMETHASONE; DIHYDROERGOTAMINE MESILATE; DIMENHYDRINATE; DOMPERIDONE; ERGOTAMINE; IBUPROFEN; KETOROLAC; METOCLOPRAMIDE; METOPROLOL; NADOLOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PETHIDINE; PROCHLORPERAZINE; PROPRANOLOL; SEROTONIN ANTAGONIST; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ALOPECIA; BRADYCARDIA; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DEPRESSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DEPRESSION; DROWSINESS; DYSPEPSIA; DYSPHORIA; EDEMA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FIBROSIS; GASTROINTESTINAL SYMPTOM; HABITUATION; HEADACHE; HUMAN; HYPOTENSION; IMPOTENCE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDER; SOMNOLENCE; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX DISEASE; TREMOR; WEIGHT GAIN; XEROSTOMIA;

EID: 0030905949     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Stewart WT, Shechter A, Rasmussen BK. Migraine prevalence: a review of population-based studies. Neurology 1994;44(6 suppl 4):S17-S23.
2. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among misraineurs: a national probability sample. Headache 1992;32: 237-8.
3. Stewart WF, Lipton RB. Migraine headache: epidemiology and health care utilization. Cephahlgin 1993;13(suppl 12):41-6.
4. De Lissvoy G, Lazarus SS. The economic cost of migraine: present state of knowledge. Neurology 1994;44(6 suppl 4):S56-S62.
5. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993;20:131-7.
6. Stewart WF, Celentano DD, Linet MS. Disability, physician consultation and use of prescription medications in a population-based study of headache. Bionied Pharmacotber 1989;43:711 -8.
7. Linet MS, Celentano DD, Stewart WF. I leadache characteristics associated with physician consultation: a population-based survey. Am J Prev Med 1991;7:40-6.
8. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine: a comparison of symptom-based and physician diagnosis. Arch Intern Med 1992;152:1273-8.
9. Headache Classification Committee, International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):l-96.
10. Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA 1962;179:717-8.
11. Merikangas KR, Dartigues JF, Whitaker A, Angst J. Diagnostic criteria for migraine: a validity study. Neurology 1994;44(6 suppl 4):S 11 -S 16.
12. National Academy of Sciences, Institute of Medicine. Clinical practice guidelines; directions for a ties program. Washington: National Academy Press; 1990.
13. Canadian Task Force on the Periodic Health Examination. The periodic health examination: 2. 1987 update. Can Med Assoc J 1988;118:618-26.
14. Blau JN. Towards a definition of migraine headache. Lancet 1984;1:444-5.
15. Lance, JW, Anthony M. Some clinical aspects of migraine: a prospective study of 500 patients. Arch Neurol 1966; 15:3 56-61.
16. Oleson J. Some clinical features of the migraine attack: an analysis of 750 patients. Headache 1978;18:268-71.
17. Friedman AP, Von Storch TJC, Merritt HH. Migraine and tension headache: a clinical study of two thousand cases. Neurology 1954;4:773-8.
18. Messinger HB, Spierings ELH, Vincent AJP. Overlap of migraine and tension-type headache in the IHS classification. Cephahlgia 1991;! 1:233-7.
19. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: the electroencephalogram in the evaluation of headache [summary statement]. Neurology 1995;45:1411-3.
20. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurological examinations [summary statement]. Neurology 1994;44:1353-4.
21. Kovacs K, Bors L, Tothfalusi L, Jelencsik I, et al. Cerebrospinal fluid (CSF) investigations in migraine. Cephatalgia 19S9;9:53-7.
22. Andersson PG, Hinge HH, Johansen O, et al. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 19S9;9:29-32.
23. Gawel AIJ. The use of analgesics in headache. Headache Q 1990;1:3:209-15.
24. Havanka-Kanniainen H. Treatment of acute migraine attack: Ibuprofen and placebo compared. Headache 1989;29:507-9.
25. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992;12:16971.
26. Nestvold K, Kloster R, Partinen AI, Sulkava R. Treatment of acute migraine: Naproxen and placebo compared. Headache Q 1985;1(3):211.
27. Tokola RA, Kangasniemi P, IS'euvonen PJ, et al. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia 1984;4:253-63.
28. Hakkarainen H, Allonen H. Ergotamine vs metoclopramide vs their combination in acute migraine attacks. Headache 19S2;22:10-2.
29. Kangasniemi P, Kaaja R. Ketoprofen and ergotamine in acute migraine. J Intern Med 1992;231:551-4.
30. Kinnunen E, Erkinjuntti T, Farkkila AI, et al. Placebo-controlled doubleblind trial of pirprofen and an ergotamine tartrate compound in migraine attacks. Cephalalgia 1988;8:175-9.
31. Pradalier A, Rancurel G, Dordain G, et al. Acute migraine attack therapy: comparison of naproxen sodium and ergotamine tartrate compound. Cefbalalgw 1985:5:107-13.
32. Trêves TA, Streiffler AI, Korezyn AD. Xaproxen sodium versus ergotamine tartrate in the treatment of acute migraine attacks. Headache 1992;32(6):280-2.
33. Gawel AIJ, Szalai JF, Stiglick A, et al. Evaluation of analgesics in recurring headache compared to other clinical pain models. Clin Phaniiacol Tter 1990;47(4):504-8.
34. MacGregor EA, Wilkinson AI, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 1993;13:I24-7.
35. Tfelt-Hansen P, Diesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a doubleblind study. Cepkahlgia 1984;4:107-11.
36. Peatfield RC, Petty RG, Clifford Rose F. Double blind comparison of mefenamic acid and acetaminophen (paracetamol) in migraine. Cephalalgia 1983;3:129-34.
37. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet 1991:338:782-3.
38. Gross AIL, Kay J, Turner AA1, et al. Sumatriptan in acute migraine using a novel cartridge system self-injector. Headache 1994;34(10):559-63.
39. N'appi G, Sicuteri F, Byrne AI, et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994;24I(3):138-44.
40. Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eitrop Neurol 1992;32:177-84.
41. Akpunonu BE, Mutgi AB, Federman DJ, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a muldcenter study. Ann Emerg Med 1995;25(4):464-9.
42. Banerjee AI, Findley LJ. Sumatriptan in the treatment of acute migraine with aura. Cephalalgia 1992;12:39-44.
43. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5.
44. Dahlof C, Edwards C, Toth A. Sumatriptan injection is superior to placebo in the acute treatment of migraine with regard to both efficacy and general wellbeing. Cephalalgia 1992;12:214-20
45. Henry P, d'Allens H. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. Headache 1993; 33(8):432-5.
46. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21.
47. Winner P, Ricalde O, Le Fortce B, Saper J, Margul B. A double blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-4.
48. Scherl ER, Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache 1995;35:256-9.
49. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986;26:168-71.
50. Weisz AIA, el-Raheb AI, Blumenthal HJ. Home administration of intramuscular DUE for the treatment of acute migraine headache. Headache 1994; 34:371-3.
51. Winner P, Dalessio D, Mathew N, et al. Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache 1993;33:471-5.
52. Winner P, Dalessio D, Mathew N, et al. Concomitant administration of antiemetics is not necessary' with intramuscular dihydroergotamine. Am J Emerg. Med 1994;12:138-41.
53. Dahlof C. Placebo controlled trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166-71.
54. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med 1989;18(4):360-5.
55. Jones EB, Gonzalez ER, Boggs JG, et al. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med 1994;24(2):237-41.
56. Davis CP, Torre PR, Schafer NC, et al. Ketorolac as a rapid and effective treatment of migraine headache: evaluations by patients. Am J Emerg Med 1993;ll:573-5.
57. Duarte C, Dunaway F, Turner L, et al. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: a randomized, prospective, double-blind trial. Ann Emerg Med 1992;21(9):1116-21;
58. Larkin GL, Prescott JE. A randomized, double-blind, comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine. Ann Emerg Med 1992;21 (8):919-24.
59. Turkewitz LJ, Casaly JS, Dawson GA, Wirth O, Hurst RJ, Gillette PL. Selfadministration of parcntcral ketorolac tromethamine for head pain. Headache 1992;32:452-4.
60. Elenbaas RM, lacono CU, Koellner KJ, et al. Dose effectiveness and safety of butorphanol in acute migraine headache. Phannacotherapy 1991;! I(l):56-63.
61. Hoffen MJ, Couch JR, Diamond S, et al. Transnasal butorphanol in the treatment of acute migraine. Headuche 1995;35:65-9.
62. Stielt IG, Dufour DG, Moher D, et al. Mcthotrimeprazine versus meperidine and dimenhydrinate in the treatment of severe migraine: a randomized controlled trial. Ann Emerg Med 1991;20(11):57-61.
63. Saper JR, Silberstein S, Gordon CD, et al. Handbook of headache management. Baltimore: Williams and Wilkins; 1993.
64. Stewart Johnson E, Tfelt-Hansen P. NTon-steriodal anti-inflammatory drugs. In: Diesen J, Tfelt-Hansen P, Welch KA1A, editors. The headaches. New York: Raven Press; 1993:391-5.
65. Bates D, Ashford E, Dawson R. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44:158792.
66. Kubacka RT. Practical approaches to the management of migraine. Am Phann 1994;NS34:34-44.
67. Simmons VE, Blakeborough P. The safety profile of sumatriptan. Rev Contemp Phannacother 1994;5:319-28.
68. Mathew NT. Chronic daily headache: clinical features and natural history. In: Nappi G, et al, editors. Headache and depression: serotonin pathways as a cwninon cine. New York: Raven Press; 1991:49-58.
69. Coppola AI, Yealy, DAI, Laibold, RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headaches. Ann Emerg Med 1995;26:541-6.
70. Gallagher RAI. Emergency treatment of intractable migraine. Headache 1986;26:74-5.
71. Saadah HA. Abortive headache therapy in the office with intravenous dihydroergotamine plus prochlorperazine. Headache 1992;32:143-6.
72. Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989;24;261:l 174-6.
73. Lane PL, Ross R. Intravenous chlorpromazine -preliminary results in acute migraine. Headache 1985;25:302-4.
74. Edmeads J. Emergency management of headache. Headache 1988;28:675-9.
75. Maizels AI, Scott B, Cohen W, Chen W. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA 1996;276:319-21.
76. Al-Qassab HK, Findley LJ. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. Cephalalgia 1993;13:128-31.
77. Briggs RS, Millac PA. Timolol in migraine prophylaxis. Headache 1979; 19:379-81.
78. Diamond S, Kudrow L, Stevens J, Shapiro DB. Long-term study of propranolol in the treatment of migraine. Headache 1982;22:268-71.
79. Johannsson V, Nilsson LR, Widelius T, Javerfalk T, Heilman P, et al. Atenolol in migraine prophylaxis: a double-blind cross-over multicentre study. Headache 1987;27:372-4.
80. Kuritzky A, Hering R. Prophylactic treatment of migraine with long acting propranolol: a comparison with placebo. Cephalalgia 1987;7(suppl 6):457-8.
81. Pradalier A, Serratrice G, Collard AI, Hirsch E, Fève J, et al. Double-blind placebo controlled study of the use of long-acting propranolol in migraine prophylaxis. Cephalalgia 1989;(9suppl 10):367-8.
82. Ryan Sr RE, Ryan Jr RE, Sudilovsky A. Nadolol: its use in the prophylactic treatment of migraine. Headache 1983;23:26-31.
83. Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol.y/Mt-l 1984:252:2576-9.
84. Stensrud P, Sjaastad O. Comparative trial of tenormin (atenolol) and inderal (propranolol) in migraine. Headache 1980(20:204-7.
85. Weber RB, Reinmuth OM. The treatment of migraine with propranolol. . Neurology 1972;22:366-9.
86. Wi Jeroe T, Vigander T. Propranolol in the treatment of migraine. BMJ 1974;2:699-701.
87. Albers GW, Simon LT, Hamik A, Peroutka SJ. Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache 1989;29:214-7.
88. Gawel AIJ, Kreeft J, Nelson RF, Simard D, Amort WS. Comparison of the efficacy and safer)- of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 1992;19:340-5.
89. Gerber WD, Diener HC, Scholz E, Niederberger U. Responders and nonresponders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. Cephalalgia 1991;! 1:37-45.
90. Grotemeyer KH, Schlake HP, Husstedt IW, Rolf LII. Metoprolol versus flunarizine: a double-blind cross-over study. Cephalalgia 1987;(7 suppl 6):465-6.
91. Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Ana Neurol Stand 1986;73:490-2.
92. Soelberg Sorensen P, Larsen BH, Rasmussen .MJK, Kinge E, Iversen II, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991;31:650-7.
93. Wober C, Wober-Bingol C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and bcta-blockers. Cefbalalgia 1991; 11:251-6.
94. Markley HG. Verapamil and migraine prophylaxis: mechanisms and efficacy. Am J Med 1991;90(suppl 5A):48S-53S.
95. Amery Caiers LI, Aerts TJ. Flunarizine, a calcium entry blocker in migraine prophylaxis. Headache 1985;25:249-54.
96. Havanka-Kanniainen H, Hokkanen E, Myllyla W. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia 1985;5:39-43.
97. Lamsudin R, Sadjimin T. Comparison of the efficacy between flunarizine and nifedipine in the prophylaxis of migraine. Headache 1993;33:335-8.
98. Markely HG, Cheronis JCD, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984;34:973-6.
99. AIcArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ. Nifedipine in . the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology 1989;39:284-6.
100. Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headache. Headache 1983; 23:266-77.
101. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine: a double-blind, placebo-controlled study. JAMA 1983;250:2500-2.
102. Stewart DJ, Gelston A, Hakim A. Effect of prophylactic administration of nimodipine in patients with migraine. Headache 1988;28:260-2.
103. Thomas AI, Behari M, Ahuja GK. Flunarizine in migraine prophylaxis: an Indian Trial. Headache 1991;31:613-5.
104. U'ober C, Brücke T, Wober-Bingol C, Ascnbaum S, Wessely P, Podreka I. Dopamine D2 receptor blockade and antimiuraine action of flunarizine. Cephalalgia 1994;14:235-40.
105. Capildeo R, Rose FC. Single-dose pizotifen, 1.5 mg nocte: a new approach in the prophylaxis of migraine. Headache 1982;22:272-5.
106. Lawrence ER, Hossain AI, Littlestone W. Sandomigran for migraine prophylaxis, controlled multicenter trial in general practice. Headache 1977; 17:10912.
107. Lance JW, Anthony AI, Somemlle B. Comparative trial of serotonin antagonists in the management of migraine. BMJ 1970;2:237-330. &
108. Drummond PD. Effectiveness of methysergide in relation to clinical features of migraine. Headache 1985;5:145-6.
109. Elkind A, Friedman AP, Bachman A, Siegelman SS, Sacks OW. Silent retropuritoneal fibrosis associated with methysergide therapy. JAMA 1968; 206:1041-4.
110. Lance JW, Curran DA, Anthony M. Investigations into the mechanism and treatment of chronic headache. Med J Aust 1965;2(22):909-14.
111. Seymour R. Retroperitoneal fibrosis associated with methysergide therapy for migraine. Med J Aust 1968;1:59-60.
112. Steardo L, Marano E, Barone P, Denman DW, Monteleone P, Cardone G. Prophylaxis of migraine attacks with a calcium-channel blocker: flunarizine versus methysergide.JCV/n Phannacol 1986;26(7):524-8.
113. Forssman B, Henriksson KG, Kihlstrand S. A comparison between BC 105 and methysergide in the prophylaxis of migraine. Acta Neurol Scand 1972; 48(2):204-12.
114. Presthus J. BC 105 and methysergide in migraine prophylaxis. Acta Neurol S/1971;47(4):514-8.
115. Ryan RE. Double-blind crossover comparison of EC-105, mcthysergide and placebo in the prophylaxis of migraine headache. Headache 1968;8(3):l 18-26.
116. Pedersen E, Moller CE. Methysergide in migraine prophylaxis. Clin Phanna-col Thir 1966;7(4):520-6.
117. Herrmann WM, Horowski R, Dannehl K, et al. Clinical effectiveness of lisuride hydrogen maleate: a double blind trial versus methysergide. Headache 1977;17(2):54-60.
118. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994;34:476-8.
119. Couch JR Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;3 6:695-9.
120. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:81-4.
121. Jensen R, Brinck, T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura. Neurology 1994;44:647-51.
122. Jensen R, Brinck T, Olesen J. Prophylactic effect of sodium valproate in migraine without aura: a double blind, placebo- and dose-controlled study [abstract]. Cephalalgia 1993;13(13):193.
123. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, et al. Migraine prophylaxis with divalproex. Arch Neural 1995;52:281-6.
124. Sianard-Gainko J, Lenaerts AI, Bastings E, Schoenen J. Sodium valproate in severe migraine and tension-type headache: Clinical efficacy and correlations with blood levels [abstract]. Cephalalgia 1993;13(13):252.
125. Silberstein SD, Saper JR, Mathew NT. The safety and efficacy of divalproate sodium in the prophylaxis of migraine headache: a multicenter, double-blind, placebo-controlled trial [abstract]. Headache 1993';33:264-5.
126. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Aaa Neurol Stand 1988;78:346-8.
127. Anthony AI, Lance JW. Indomethacin in migraine. Med J Aust 1968;1:56-7.
128. Mikkelsen BAI, Falk JV. Prophylactic treatment of migraine with tolfenamic acid: a comparative double blind crossover study between tolfenamic acid and placebo. Aaa Neurol Scan J 1982;66:105-11.
129. Pradalier A, Clapin A, Dr)'J. Treatment review: non steroid anti-inflammatory drugs in the treatment and long-term prevention of migraine attacks. Headache 1988;28:550-7.
130. Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen (19.583 R.P.) in migraine prophylaxis. Headache 1974;14:96-100.
131. Welch KAIA, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985;35:I304-10.
132. Raskin Nil, Schwanz RK. Interval therapy of migraine: long-term results. Headache 1980;20:336-40.
133. Purdy RA. Headache in adults. In: Patterson C, editor. Therapeutic choices. Ottawa: Canadian Pharmaceutical Association; 1995:87-94.
134. Raskin Nil. Acute and prophylactic treatment of migraine: Practical approaches and pharmacologie rationale. Neurology 1993;43(6 suppl 3):S39-S42.
135. Silberstein SD, Lipton RB. Overview of diagnosis and treatment of migraine. Neurology 1994;44(10 suppl 7):S6-S16.
136. Welch KAIA. Drugtherapy of migraine. N Engl J Med 1993;329:1476-83.
137. Worthington I. Current migraine therapy. Can J Clin Pharmacol 1996; 36(1):39-51.
138. Drugs for migraine. Med Lett 1995;37(943):17-20.
139. Olesen J, Tfelt-Hansen P, Welch KAIA, editors. The headaches. New York: Raven Press; 1993.
140. Purdy RA. In: Edmeads J, editor. Migraine: a handbook for pharmacists. Toronto: Grosvenor House Press; 1992.
141. Raskin NH. Headache. 2nd ed. New York: Churchill Livingstone; 1988.
142. Couch JR, Ziegler DK, Hassanein RS. Evaluation of the relationship between migraine headaches and depression. Headache 1975;15:41-50.
143. Diamond S, Solomon GD, Freitag FG, Mehta N. Selection of patients: critical aspects. Neuroepidemiohgy 1987;6:172-7.
144. Tfelt-Hansen P, Welch KAIA. General principles of pharmacological treatment. In: Olsen J, Tfelt-Hansen P, Welch KAIA, editors. The headaches. New York: Raven Press; 1993:299-303.
145. Diener HC. A review of current treatments for migraine. Eur Neurol 1994; 34(suppl2):18-25.
146. Tfelt-Hansen P, Shanks RG. ß-adrenoreceptor blocking drugs. In: Olesen J. Tfelt-Hansen P, Welch KAIA, editors. The headaches. New York: Raven Press; 1993:363-71.
147. Hardman JG, Limberd LE, editors. Goodman and Gilntan''; thephannacologkal basis of therapeutics. 9th ed. New York: AIcGraw Hill; 1996.
148. Fullerton T. Recent advances in the understanding and treatment of mi graine. Pharmacy Pract 1993;6:53-270.
149. Lance JW. Treatment of migraine. Lancet 1992;339:1207-9.
150. Todas N, Tfelt-Hansen P. Calcium antagonists. In: Olsen J, Tfelt-Hansen P, Welch KAIA, editors. The headaches. New York: Raven Press; 1993:383-90.
151. Spight TAI, Avery GS. Pizotifen (BC 105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 1992; 3:159-203.
152. Tfelt-I lansen P, Saxena PR. Antiserotonin drugs. In: Olsen J, Tfelt-Hansen P, Welch KAIA, editors. The headaches. New York: Raven Press; 1993:373-82.
153. Mylecharane EJ, Tfclt-Hansen P. Miscellaneous drugs. In: Diesen J, Tfelt-Elansen P, Welch KMA, editors. The bfttdacbes. New York: Raven Press; 1993:397-402.
154. Saper JR, Silberstcin JD, Lake AE, Winters ME. Double blind trial of fluoxetine: chronic daily headache and migraine. HMacbe 1994;34:497-502.
155. Adly C, Straumanes J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992;32:101-4.
156. Goulden KJ, Dooley JM, Camfield PK, Fraser AD. Clinical valproate toxicity induced by acetylsalicylic acid. Xeurolog/ 1987;37:1392.
157. Gunthrie SK, Sroysich AM, Bader G, Hilleman DE. I lypothesized interaction between valproic acid and warfarin. J din Pycbophannacol 1995;! 5:138.
158. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines, lleadacke 1996;36:547-55.
159. Sance G, Martignoni E, Fioroni L, et al. Naproxcn sodium in menstrual migraine prophylaxis: a double-blind placebo-controlled study. Headache 1990;30:705-9.
160. Szekely B, Merryman S, Croft H, Post G. Prophylactic effects of naproxen sodium on perimenstrual headache: a double-blind, placebo-controlled study. Ctfbalalgia 1989;9(suppl 10):452-3.
161. Reprint requests to: Dr. William E.M. Pryse-Phillips, Division of Neurology, Health Sciences Centre, St. John's NF A1B 3V6; fax 709 737-6656; wpryse@morgan.ucs.mun.ca About the authors: Dr. Pryse-Phillips is Professor of Medicine (Neurology) at Memorial University of Newfoundland and a neurologist at the Health Science Centre, St. John's, Nfld.; Dr. Dodick is Senior Associate Consultant with the Department of Neurology, Mayo Clinic and Mayo Foundation, and Assistant Professor of Neurology, Mayo Medical School, Rochester, Minn.; Dr. Edmeads is Physician-in-Chief at the Sunnybrook Health Science Centre, North York, Ont.; Dr. Gawel is President of the Canadian Headache Society, Assistant Professor of Medicine, University of Toronto, and a consultant neurologist with the Scarborough Centenary Health Centre, Scarborough, Ont., and Sunnybrook Health Science Centre, North York, Ont.; Dr. Nelson is Professor of Medicine (Neurology) at the University of Ottawa and Director of the Migraine Clinic, Ottawa General Hospital, Ottawa, Ont.; Dr. Purdy is Professor of Medicine (Neurology) at Dalhousie University and Head of the Division of Neurology, Queen Elizabeth II Health Sciences Centre, Halifax, NS; Dr. Robinson is Clinical Associate Professor at the University of British Columbia and a staff neurologist at the Vancouver Hospital and Health Sciences Centre, Vancouver, BC; Dr. Stirling is a neurologist at the Oakville Trafalgar Memorial Hospital, Oakville, Ont.; and Ms. Worthington is with the Drug Information Centre (Metrodis), University of Toronto, Sunnybrook Health Science Centre, Toronto, Ont.